Global return-on-investment of COVID-19 vaccines in the first year of the vaccination programme: A model-based economic evaluation
PLOS Medicine · 05.11.2026 · 23 (11) · e1004772
DOI: 10.1371/journal.pmed.1004772 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Medicine, online erschienen am 05.11.2026. Verfasst von Hallie Benjamin und 3 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Public Health and Policy, London School of Hygiene and Tropical Medicine, London, United Kingdom. Hauptthemen laut MEDLINE: COVID-19 Vaccines, COVID-19, Immunization Programs, Vaccination. Die Arbeit nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute for Health Research Health Protection Research Unit, Imperial College and Eric and Wendy Schmidt AI in Science Fellowship, a program of Schmidt Sciences, Centre funding from the UK Medical Research Council, Community Jameel.
Abstract (Originalsprache)
Background
COVID-19 vaccines played a critical role in reducing global health burden during the COVID-19 pandemic, but their rapid development required extraordinary effort. This study aims to evaluate their global return-on-investment (ROI) during the first year of the vaccination programme (8 December 2020–8 December 2021) to provide insights into the economic benefits relative to the costs of vaccine development, manufacturing, and delivery. Methods and findings Public health outcomes of COVID-19 vaccination, including life years and quality-adjusted life years (QALYs) gained from averted deaths, infections, and hospitalizations, were estimated. Health benefits were valued using two approaches: i) cost-benefit analysis and ii) cost-effectiveness analysis. These benefits were compared to the costs of vaccine development, manufacturing, and delivery to estimate the ROI under both approaches. Probabilistic sensitivity analyses were conducted to assess the impact of parameter uncertainty on ROI estimates. Vaccine development and delivery cost $79.4 billion, but the health and economic benefits of vaccination were valued between $6.43 and $64.3 trillion. High-income countries saw the greatest health benefits per-person vaccinated, and low-income countries gained the greatest nonhealth benefits per-person vaccinated, when expressed as a proportion of gross domestic product per capita. This estimated ROIs of $59.7–$809 per dollar invested in the base case analysis. ROIs ranged between $60.3–$753 across probabilistic sensitivity analyses for both approaches. Limitations include reliance on previous analyses of COVID-19 vaccination impact and a time horizon limited to the first year of COVID-19 vaccination.
Conclusions
Rapid COVID-19 vaccine development and delivery were an excellent investment. Vaccine development and equitable vaccine distribution globally should be prioritized before and during global health crises.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Faculty of Public Health and Policy, London School of Hygiene and Tropical Medicine, London, United Kingdom.
- Department of Infectious Disease Epidemiology, Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, United Kingdom.
- MRC Centre for Global Infectious Disease Analysis, Imperial College London, London, United Kingdom.
- Department of Global and Environmental Health, School of Global Public Health, New York University, New York, United States of America.
ORCID-Profile: Hallie Benjamin, Gregory Barnsley, Oliver J Watson, Mark Jit
Förderung
- National Institute for Health Research Health Protection Research Unit
- Imperial College and Eric and Wendy Schmidt AI in Science Fellowship, a program of Schmidt Sciences, Centre funding from the UK Medical Research Council
- Community Jameel
- Medical Research Council
Zitieren
APA
Benjamin, H., Barnsley, G., Watson, O. J., & Jit, M. (2026). Global return-on-investment of COVID-19 vaccines in the first year of the vaccination programme: A model-based economic evaluation. PLOS Medicine, 23(11), e1004772. https://doi.org/10.1371/journal.pmed.1004772
Vancouver
Benjamin H, Barnsley G, Watson OJ, Jit M. Global return-on-investment of COVID-19 vaccines in the first year of the vaccination programme: A model-based economic evaluation. PLOS Medicine. 2026;23(11):e1004772. doi:10.1371/journal.pmed.1004772
BibTeX
@article{Benjamin2026,
author = {Benjamin, Hallie and Barnsley, Gregory and Watson, Oliver J and Jit, Mark},
title = {Global return-on-investment of COVID-19 vaccines in the first year of the vaccination programme: A model-based economic evaluation},
journal = {PLOS Medicine},
year = {2026},
volume = {23},
number = {11},
pages = {e1004772},
doi = {10.1371/journal.pmed.1004772}
}
EUVIMED